Antipsychotic trials in schizophrenia : (Record no. 521366)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 03619nam a22003618i 4500 |
| 001 - CONTROL NUMBER | |
| control field | CR9780511712265 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | UkCbUP |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20200124160315.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS--GENERAL INFORMATION | |
| fixed length control field | m|||||o||d|||||||| |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr|||||||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 100225s2010||||enk o ||1 0|eng|d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9780511712265 (ebook) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Cancelled/invalid ISBN | 9780521895330 (hardback) |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | UkCbUP |
| Language of cataloging | eng |
| Description conventions | rda |
| Transcribing agency | UkCbUP |
| 050 00 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RM333.5 |
| Item number | .A58 2010 |
| 082 00 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 616.89/8061 |
| Edition number | 22 |
| 245 00 - TITLE STATEMENT | |
| Title | Antipsychotic trials in schizophrenia : |
| Remainder of title | the CATIE project / |
| Statement of responsibility, etc | edited by T. Scott Stroup, Jeffrey A. Lieberman. |
| 264 #1 - Production, Publication, Distribution, Manufacture, and Copyright Notice (R) | |
| Place of production, publication, distribution, manufacture (R) | Cambridge : |
| Name of producer, publisher, distributor, manufacturer (R) | Cambridge University Press, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2010. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (xvii, 312 pages) : |
| Other physical details | digital, PDF file(s). |
| 336 ## - Content Type (R) | |
| Content type term (R) | text |
| Content type code (R) | txt |
| Source (NR) | rdacontent |
| 337 ## - Media Type (R) | |
| Media type term (R) | computer |
| Media type code (R) | c |
| Source (NR) | rdamedia |
| 338 ## - Carrier Type (R) | |
| Carrier type term (R) | online resource |
| Carrier type code (R) | cr |
| Source (NR) | rdacarrier |
| 500 ## - GENERAL NOTE | |
| General note | Title from publisher's bibliographic system (viewed on 05 Oct 2015). |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Machine generated contents note: Introduction: Rationale for an independent, pragmatic study of antipsychotic treatments Jeffrey Lieberman; 1. Study design and protocol development process Scott Stroup, Joe McEvoy and Jeffrey Lieberman; 2. Statistical considerations Sonia Davis and Gary Koch; 3. Efficacy and effectiveness Joe McEvoy, Scott Stroup and Jeffrey Lieberman; 4. Measures of global effectiveness, cost-effectiveness Bob Rosenheck; 5. Quality of life and recovery Marvin Swartz; 6. Neurocognition Rich Keefe; 7. Vocational outcomes Sandra Resnick et al.; 8. Family outcomes Deborah Perlick et al.; 9. Neurologic side effects Stan Caroff, Del Miller and Bob Rosenheck; 10. Metabolic side effects and risk of cardiovascular disease Jonathan Meyer, Don Goff and Joe McEvoy; 11. Substance abuse Fred Reimherr and Marvin Swartz; 12. Violence Jeff Swanson and Richard van Dorn; 13. Genetics Patrick Sullivan; 14. Human subjects considerations Scott Stroup, Scott Kim and Paul Appelbaum; 15. Pharmacokinetics Bruce Pollock; 16. Implications of the CATIE project on research design and implementation Scott Stroup and Jeffrey Lieberman; 17. Conclusions-impact of the study and implications for dissemination, practice and policy formation Scott Stroup, Bob Rosenheck and Jeffrey Lieberman; Index. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc | Antipsychotic medications are a key treatment for schizophrenia and sales of antipsychotic drugs approach $20 billion per year, with fierce marketing between the makers of the drugs. The U.S. National Institute of Mental Health sponsored the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project to provide independent information about the comparative effectiveness of medications. CATIE was the largest, longest and most comprehensive study of schizophrenia to date. Conducted under rigorous double-blind conditions, Antipsychotic Trials in Schizophrenia presents the definitive archival results of this landmark study. The core of the book consists of chapters focused on specific outcomes that set the CATIE findings in a wider context. Also included are chapters on the design, statistical analyses and implications for researchers, clinicians and policy makers. Psychiatrists, psychiatric researchers, mental health policy makers and those working in pharmaceutical companies will all find this to be essential reading. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Antipsychotic drugs |
| General subdivision | Testing. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Schizophrenia |
| General subdivision | Chemotherapy. |
| 610 20 - SUBJECT ADDED ENTRY--CORPORATE NAME | |
| Corporate name or jurisdiction name as entry element | CATIE Project. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Stroup, T. Scott, |
| Dates associated with a name | 1960- |
| Relator term | editor. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Lieberman, Jeffrey A., |
| Dates associated with a name | 1948- |
| Relator term | editor. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Display text | Print version: |
| International Standard Book Number | 9780521895330 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1017/CBO9780511712265">https://doi.org/10.1017/CBO9780511712265</a> |
No items available.